{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:07:14Z","timestamp":1794006434871,"version":"4.8.0"},"reference-count":47,"publisher":"IOP Publishing","issue":"24","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"Australian Government Research Training Program","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Phys. Med. Biol."],"published-print":{"date-parts":[[2025,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Objective.<\/jats:italic>\n                    Pancreatic adenocarcinoma (PDAC) is notoriously difficult to treat due to treatment-resistance and the pancreas\u2019 proximity to organs at risks (OARs). Tumour hypoxia further complicates treatment, with substantial intra- and inter-tumour heterogeneity limiting predictability of treatment response, and often requiring multimodal therapy. Proton beam therapy (PBT) with concurrent chemotherapy has been proposed as a promising alternative for patients with locally-advanced unresectable disease. This study aims to evaluate the impact of tumour hypoxia on PBT outcomes in PDAC, and whether concurrent chemotherapy can offset hypoxia-related reductions in local control.\n                    <jats:italic>Approach.<\/jats:italic>\n                    Thirty PBT treatment plans from previous work were utilised. An\n                    <jats:italic>in silico<\/jats:italic>\n                    model was developed to generate multiple hypoxia scenarios within plausible bounds reported in literature on PDAC. The effect of intra-fraction reoxygenation was modelled, followed by the addition of concurrent gemcitabine-based chemotherapy from clinical data. For each scenario, three-dimensional distributions of biologically effective dose, survival fraction, and tumour control probability were evaluated.\n                    <jats:italic>Main results.<\/jats:italic>\n                    Tumour hypoxia significantly reduced the weighted average TCP in larger internal target volumes, particularly where PBT dose was constrained by proximity to OARs. Intra-fraction reoxygenation improved TCP by up to 13.4% [95%CI:6.5, 20.4], and was most effective in tumours with high-grade hypoxia and dose-limited regions. Chemotherapy improved TCP by up to 21.9% [95%CI:20.1, 26.2], though its benefit mitigated dose-loss due to nearby OARs rather than directly mitigating hypoxia.\n                    <jats:italic>Significance.<\/jats:italic>\n                    These findings highlight the importance of considering hypoxia and spatial dose limitations when evaluating treatment efficacy with PBT. Quantifying tumour hypoxia and reoxygenation dynamics before and during treatment could offer insight into local control outcomes. Concurrent chemotherapy can enhance tumour control, but its effect is more influenced by surrounding anatomy than hypoxia, suggesting that while it improves local control, it is insufficient as a standalone treatment for locally-advanced PDAC.\n                  <\/jats:p>","DOI":"10.1088\/1361-6560\/ae273b","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T23:03:38Z","timestamp":1764716618000},"page":"245008","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Modelling the impact of tumour hypoxia on proton therapy and concurrent chemotherapy on locally advanced pancreatic cancer\u2014insights from an\n                    <i>in silico<\/i>\n                    study"],"prefix":"10.1088","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-6925","authenticated-orcid":true,"given":"Melissa","family":"Anne McIntyre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-7691","authenticated-orcid":false,"given":"Puthenparampil","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-0978","authenticated-orcid":false,"given":"Peter","family":"Gorayski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-1735","authenticated-orcid":false,"given":"Eva","family":"Bezak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"pmbae273bbib1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/diagnostics13040655","type":"journal-article","article-title":"Tumor stroma area and other prognostic factors in pancreatic ductal adenocarcinoma patients submitted to surgery","volume":"13","author":"Amaral","year":"2023","journal-title":"Diagnostics"},{"key":"pmbae273bbib2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijrobp.2024.12.020","type":"journal-article","article-title":"Proton beam therapy for pancreatic tumors: a consensus statement from the particle therapy cooperative group gastrointestinal subcommittee","volume":"122","author":"Arpit","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"pmbae273bbib3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","type":"journal-article","article-title":"Randomized phase II trial of gemcitabine plus th-302 versus gemcitabine in patients with advanced pancreatic cancer","volume":"33","author":"Borad","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"pmbae273bbib4","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/1097-0142(20001201)89:11<2222::AID-CNCR10>3.0.CO;2-V","type":"journal-article","article-title":"Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma","volume":"89","author":"Ceha","year":"2000","journal-title":"Cancer"},{"key":"pmbae273bbib5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1533034616650778","type":"journal-article","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol. Cancer Res. Treat."},{"key":"pmbae273bbib6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jrr\/rrw016","type":"journal-article","article-title":"Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer","volume":"57","author":"Crane","year":"2016","journal-title":"Radiat. Res."},{"key":"pmbae273bbib7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","type":"journal-article","article-title":"Phenotype and genotype of pancreatic cancer cell lines","volume":"39","author":"Deer","year":"2010","journal-title":"Pancreas"},{"key":"pmbae273bbib8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12010163","type":"journal-article","article-title":"Clinical limitations of photon, proton and carbon ion therapy for pancreatic cancer","volume":"12","author":"Dell\u2019Oro","year":"2020","journal-title":"Cancers"},{"key":"pmbae273bbib9","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/bjc.2015.284","type":"journal-article","article-title":"Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole","volume":"113","author":"Dhani","year":"2015","journal-title":"Br. J. Cancer"},{"key":"pmbae273bbib10","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101250","type":"journal-article","article-title":"Proton therapy for unresectable and medically inoperable locally advanced pancreatic cancer: results from a multi-institutional prospective registry","volume":"8","author":"Eckstein","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"pmbae273bbib11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/bjc.2014.610","type":"journal-article","article-title":"Imaging tumour hypoxia with positron emission tomography","volume":"112","author":"Fleming","year":"2015","journal-title":"Br. J. Cancer."},{"key":"pmbae273bbib12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00000658-199602000-00006","type":"journal-article","article-title":"Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy","volume":"223","author":"Fortner","year":"1996","journal-title":"Ann. Surg."},{"key":"pmbae273bbib13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00006676-200105000-00005","type":"journal-article","article-title":"Growth rate of pancreatic adenocarcinoma: initial clinical experience","volume":"22","author":"Furukawa","year":"2001","journal-title":"Pancreas"},{"key":"pmbae273bbib14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3892\/ijo.2011.1254","type":"journal-article","article-title":"Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype","volume":"40","author":"Gang","year":"2012","journal-title":"Int. J. Oncol."},{"key":"pmbae273bbib15","doi-asserted-by":"publisher","DOI":"10.1088\/2057-1976\/ac9b5d","type":"journal-article","article-title":"Hypoxia adapted relative biological effectiveness models for proton therapy: a simulation study","volume":"8","author":"Garrido-Hernandez","year":"2022","journal-title":"Biomed. Phys. Eng. Express"},{"key":"pmbae273bbib16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40658-022-00479-7","type":"journal-article","article-title":"Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters","volume":"9","author":"Gholami","year":"2022","journal-title":"EJNMMI Phys."},{"key":"pmbae273bbib17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000267","type":"journal-article","article-title":"Preoperative\/Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med."},{"key":"pmbae273bbib18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1287459","type":"journal-article","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front. Immunol."},{"key":"pmbae273bbib19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1634\/theoncologist.2018-0266","type":"journal-article","article-title":"Pancreas cancer-associated weight loss","volume":"24","author":"Hendifar","year":"2019","journal-title":"Oncologist"},{"key":"pmbae273bbib20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.radonc.2019.03.012","type":"journal-article","article-title":"Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer","volume":"136","author":"Hiroshima","year":"2019","journal-title":"Radiother. Oncol."},{"key":"pmbae273bbib21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4240\/wjgs.v9.i4.103","type":"journal-article","article-title":"Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer","volume":"9","author":"Hitchcock","year":"2017","journal-title":"World J. Gastrointest Surg."},{"key":"pmbae273bbib22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","type":"journal-article","article-title":"Tumor hypoxia: definitions and current clinical, biologic and molecular aspects","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J. Natl Cancer Inst."},{"key":"pmbae273bbib23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1476-4598-8-125","type":"journal-article","article-title":"Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines","volume":"8","author":"Huanwen","year":"2009","journal-title":"Mol. Cancer"},{"key":"pmbae273bbib24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0360-3016(86)90080-5","type":"journal-article","article-title":"Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response","volume":"12","author":"Kallman","year":"1986","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"pmbae273bbib25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1748-717X-9-192","type":"journal-article","article-title":"The analysis of respiration-induced pancreatic tumor motion based on reference measurement","volume":"9","author":"Knybel","year":"2014","journal-title":"Radiat. Oncol."},{"key":"pmbae273bbib26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0360-3016(00)00803-8","type":"journal-article","article-title":"Pancreatic tumors show high levels of hypoxia","volume":"48","author":"Koong","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"pmbae273bbib27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.radonc.2018.11.002","type":"journal-article","article-title":"Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma","volume":"132","author":"Lin","year":"2019","journal-title":"Radiother. Oncol."},{"key":"pmbae273bbib28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1748-717X-9-149","type":"journal-article","article-title":"Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability","volume":"4","author":"Lindblom","year":"2014","journal-title":"Radiat. Oncol."},{"key":"pmbae273bbib29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mp.14212","type":"journal-article","article-title":"Investigating the impact of alpha\/beta and LETd on relative biological effectiveness in scanned proton beams: An in vitro study based on human cell lines","volume":"47","author":"Mara","year":"2020","journal-title":"Med. Phys."},{"key":"pmbae273bbib30","article-title":"pydicom\/pydicom: pydicom 3.0.1","author":"Mason","year":"2024","type":"other"},{"key":"pmbae273bbib31","article-title":"Patient-specific modeling of dose-escalated proton beam therapy for locally advanced pancreatic cancer","author":"McIntyre","year":"2025","type":"preprint"},{"key":"pmbae273bbib32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1259\/bjr.20130676","type":"journal-article","article-title":"Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br. J. Radiol."},{"key":"pmbae273bbib33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2967\/jnumed.115.167650","type":"journal-article","article-title":"Measurement of tumor hypoxia in patients with advanced pancreatic cancer based on 18f-fluoroazomyin arabinoside uptake","volume":"12","author":"Metran-Nascente","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"pmbae273bbib34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijrobp.2021.03.021","type":"journal-article","article-title":"A novel analytical population tumor control probability model includes cell density and volume variations: application to canine brain tumor","volume":"110","author":"Radonic","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"pmbae273bbib35","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","type":"journal-article","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"pmbae273bbib36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/jgo-21-593","type":"journal-article","article-title":"Dose-escalated proton therapy with elective nodal irradiation and concomitant chemotherapy for unresectable, borderline resectable, or medically inoperable pancreatic cancer: a phase II trial","volume":"13","author":"Rapp","year":"2022","journal-title":"J. Gastroint. Oncol."},{"key":"pmbae273bbib37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360629","type":"journal-article","article-title":"High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment","volume":"15","author":"Sadozai","year":"2024","journal-title":"Front. Immunol."},{"key":"pmbae273bbib38","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101577","type":"journal-article","article-title":"Clinical outcomes of proton beam therapy for unresectable locally advanced pancreatic cancer: a single-center retrospective study","volume":"9","author":"Seto","year":"2024","journal-title":"Adv. Radiat. Oncol."},{"key":"pmbae273bbib39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ijrobp.2019.06.1932","type":"journal-article","article-title":"Pancreatic tumor motion with respiration is decreased for post-operative local recurrences relative to patients with an intact pancreas","volume":"105","author":"Stachelek","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"pmbae273bbib40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijrobp.2010.01.027","type":"journal-article","article-title":"Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer","volume":"80","author":"Sudo","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"pmbae273bbib41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3892\/ol.2023.13847","type":"journal-article","article-title":"Distribution characteristics and clinical significance of infiltrating T cells in the tumor microenvironment of pancreatic cancer","volume":"25","author":"Sun","year":"2023","journal-title":"Oncol. Lett."},{"key":"pmbae273bbib42","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s41598-019-57364-0","type":"journal-article","article-title":"Quantifying reoxygenation in pancreatic cancer during stereotactic body radiotherapy","volume":"10","author":"Taylor","year":"2020","journal-title":"Sci. Rep."},{"key":"pmbae273bbib43","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/141087","type":"journal-article","article-title":"Modelling tumour oxygenation, reoxygenation and implications on treatment outcome","volume":"2013","author":"Toma-Dasu","year":"2014","journal-title":"Comput. Math. Methods"},{"key":"pmbae273bbib44","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.3390\/ijms22136825","type":"journal-article","article-title":"Gemcitabine-based chemoradiotherapy enhanced by a PARP inhibitor in pancreatic cancer cell lines","volume":"22","author":"Waissi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"pmbae273bbib45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1088\/0031-9155\/38\/6\/001","type":"journal-article","article-title":"A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density","volume":"38","author":"Webb","year":"1993","journal-title":"Phys. Med. Biol."},{"key":"pmbae273bbib46","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","type":"journal-article","article-title":"ARCII: a phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer","volume":"119","author":"Wilson","year":"2016","journal-title":"Radiother. Oncol."},{"key":"pmbae273bbib47","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13046-018-0972-3","type":"journal-article","article-title":"Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT\/Notch1 signaling","volume":"38","author":"Zhang","year":"2018","journal-title":"Cancer Res."}],"container-title":["Physics in Medicine &amp; Biology"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:19:12Z","timestamp":1765444752000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/1361-6560\/ae273b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":47,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2025,12,21]]}},"URL":"https:\/\/doi.org\/10.1088\/1361-6560\/ae273b","relation":{},"ISSN":["0031-9155","1361-6560"],"issn-type":[{"value":"0031-9155","type":"print"},{"value":"1361-6560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"Modelling the impact of tumour hypoxia on proton therapy and concurrent chemotherapy on locally advanced pancreatic cancer\u2014insights from an\n                      in silico\n                      study","name":"article_title","label":"Article Title"},{"value":"Physics in Medicine & Biology","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2025 The Author(s). Published on behalf of Institute of Physics and Engineering in Medicine by IOP Publishing Ltd","name":"copyright_information","label":"Copyright Information"},{"value":"2025-08-10","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2025-12-02","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2025-12-11","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}